Alkermes Details $8M Equity Package for Incoming CEO Blair Jackson, Adds President Title and Board Seat
ALKS sits 97% above its 52-week low of $25.165.
Summary
Alkermes disclosed the compensation for incoming CEO Blair Jackson, including $8 million in target equity awards, a $900,000 salary, and his appointment as President and a board director, effective August 1, 2026.
Key Events · Executive and Board Changes · ALKS
-
CEO Compensation Revealed
Blair Jackson's package as President and CEO includes a $900,000 base salary, target cash bonus of 100% of base, a $5M promotion equity award (55% PSUs, 45% time-vesting options), and a $3M special incentive equity award (performance-vesting options with stock-price hurdles).
-
Expanded Role and Board Seat
Jackson was also appointed President of the company and a member of the Board of Directors and its Financial Operating Committee, effective August 1, 2026.
-
Employment Agreement Terms
Jackson's new employment agreement provides 18 months of severance (base + bonus) for non-CIC termination, and enhanced severance (2x base + bonus) if terminated within 24 months after a change in control.
-
Follows Earlier Appointment Announcement
This 8-K/A supplements the original February 25, 2026 8-K that announced Jackson would become CEO on August 1, 2026, but had deferred compensation details.
Analysis · ALKS · Life Sciences
This amendment to the February 2026 CEO appointment filing reveals the compensation package for Blair Jackson as he steps into the President and CEO role effective August 1, 2026. The package includes a $900,000 base salary, a target bonus of 100% of base, and two equity awards totaling $8 million in target value — a $5 million promotion award and a $3 million special incentive award tied to stock-price performance. Jackson also joins the board. The disclosure fills a key gap for investors: the cost and structure of the leadership transition at a company that just reported strong Q2 revenue but wider GAAP losses.
At the time of this filing, ALKS was trading at $49.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3B. The 52-week trading range was $25.17 to $55.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.